LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Despite advances in identifying the key immunoregulatory roles of many of the human leukocyte immunoglobulin-like receptor (LILR) family members, the function of the inhibitory molecule LILRB3 (ILT5, CD85a, LIR3) remains unclear. Studies indicate a predominant myeloid expression; however, high homology within the LILR family and a relative paucity of reagents have hindered progress toward identifying the function of this receptor. To investigate its function and potential immunomodulatory capacity, a panel of LILRB3-specific monoclonal antibodies (mAbs) was generated. LILRB3-specific mAbs bound to discrete epitopes in Ig-like domain 2 or 4. LILRB3 ligation on primary human monocytes by an agonistic mAb resulted in phenotypic and functional changes, leading to potent inhibition of immune responses in vitro, including significant reduction in T cell proliferation. Importantly, agonizing LILRB3 in humanized mice induced tolerance and permitted efficient engraftment of allogeneic cells. Our findings reveal powerful immunosuppressive functions of LILRB3 and identify it as an important myeloid checkpoint receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
Picarda, E., Ohaegbulam, K. C., & Zang, X. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2428 · Cited by 582 · cited 4×
“Picarda E, Ohaegbulam KC, Zang X. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.”
BackgroundInfluentialThe B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., et al. (2003) · Nature Immunology · doi:10.1038/ni967 · Cited by 576 · cited 1×
“Similarly, the reported upregulation of immunoinhibitory receptors, such as CD276 (B7-H3), upon LILRB3 ligation on myeloid cells may restrain the activation of T cells and their proliferative capacity (56, 57).”
BackgroundLILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration
Deng, M., Gui, X., Kim, J., Xie, L., Chen, W., Li, Z., He, L., Chen, Y., Chen, H., Luo, W., et al. (2018) · Nature · doi:10.1038/s41586-018-0615-z · Cited by 305 · cited 1×
“Furthermore, recent data by Zhang and colleagues suggest that LILRB4 signaling in leukemia cells mediates T cell suppression and supports tumor cell dissemination to distal organs (59).”
BackgroundLILRB receptor-mediated regulation of myeloid cell maturation and function
van der Touw, W., Chen, H.-M., Pan, P.-Y., & Chen, S.-H. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2023-x · Cited by 167
Hirayasu, K., & Arase, H. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.64 · Cited by 129
Cited by
Ali, M., Timsina, J., Western, D., Liu, M., Beric, A., Budde, J., Do, A., Heo, G., Wang, L., Gentsch, J., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.02.014 · Cited by 61
Human leukocyte immunoglobulin-like receptors in health and disease
Redondo-García, S., Barritt, C., Papagregoriou, C., Yeboah, M., Frendeus, B., Cragg, M. S., & Roghanian, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1282874 · Cited by 53
Self-citationLeukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
Deng, M., Chen, H., Liu, X., Huang, R., He, Y., Yoo, B., Xie, J., John, S., Zhang, N., An, Z., et al. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab002 · Cited by 53
LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Huang, R., Liu, X., Kim, J., Deng, H., Deng, M., Gui, X., Chen, H., Wu, G., Xiong, W., Xie, J., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0496 · Cited by 24
Metadata
- Authors
- Yeboah, M., Papagregoriou, C., Jones, D. C., Chan, H. T. C., Hu, G., McPartlan, J. S., Schiött, T., Mattson, U., Mockridge, C. I., Tornberg, U.-C., Hambe, B., Ljungars, A., Mattsson, M., Tews, I., Glennie, M. J., Thirdborough, S. M., Trowsdale, J., Frendeus, B., Chen, J., Cragg, M. S., & Roghanian, A.
- Venue
- JCI Insight
- Published
- 2020-09-01
- Volume
- 5
- Issue
- 18
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W3082377112
- Cited by
- 59
- References
- 6
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation. https://app.cochat.ai/papers/10.1172/jci.insight.141593
- The paper
- Yeboah, M., Papagregoriou, C., Jones, D. C., Chan, H. T. C., Hu, G., McPartlan, J. S., Schiött, T., Mattson, U., Mockridge, C. I., Tornberg, U.-C., Hambe, B., Ljungars, A., Mattsson, M., Tews, I., Glennie, M. J., Thirdborough, S. M., Trowsdale, J., Frendeus, B., Chen, J., . . . Roghanian, A. (2020). LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation. JCI Insight. https://doi.org/10.1172/jci.insight.141593
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.